Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation

被引：5
|
作者：
Wolf, J. [1 ]
Heist, R. [2 ]
Kim, T. M. [3 ]
Nishio, M. [4 ]
Dooms, C. [5 ]
Kanthala, R. R. [6 ]
Leo, E. [7 ]
Giorgetti, E. [7 ]
Wang, Y. [8 ]
Mardjuadi, F. I. [8 ]
Cortot, A. [9 ]
机构：
[1] Univ Klinikum Koln AoR, Dept Internal Med 1, Ctr Integrated Oncol, Cologne, Germany
[2] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA
[3] Seoul Natl Univ, Coll Med, Dept Internal Med, Yeongeon Med Campus, Seoul, South Korea
[4] JFCR, Canc Inst Hosp, Dept Thorac Med Oncol, Koto Ku, Tokyo, Japan
[5] Univ Hosp Leuven, UZ Leuven, Dept Resp Dis, Campus Gasthuisberg, Leuven, Belgium
[6] Novartis Healthcare Pvt Ltd, GDO DO Stat Programming, Hyderabad, Telangana, India
[7] Novartis Pharma AG, Oncol, Basel, Switzerland
[8] Novartis Inst BioMed Res Co Ltd, Oncol, Shanghai, Peoples R China
[9] Univ Lille, CHU Lille, Thorac Oncol Dept,Inst Pasteur Lille, CNRS,Inserm,UMR9020,UMR S 1277 Canther, Lille, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
994P
引用
收藏
页码：S1007 / S1008
页数：2
相关论文
共 50 条
  • [31] Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
    Paik, P.
    Sakai, H.
    Felip, E.
    Veillon, R.
    Garassino, M. C.
    Raskin, J.
    Viteri, S.
    Mazieres, J.
    Cortot, A.
    Smit, E.
    Thomas, M.
    Cho, B. C.
    Conte, P.
    Yang, J. C.
    Morise, M.
    Chen, Y.
    Park, K.
    Gottfried, M.
    Britschgi, C.
    Bruns, R.
    Otto, G.
    Johne, A.
    Le, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S174 - S174
  • [32] Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from VISION cohort A
    Sakai, Hiroshi
    Morise, Masahiro
    Felip, Enriqueta
    Veillon, Remi
    Garassino, Marina Chiara
    Raskin, Jo
    Viteri, Santiago
    Mazieres, Julien
    Cortot, Alexis B.
    Smit, Egbert
    Thomas, Michael
    Cho, Byoung Chul
    Conte, Pierfranco
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Park, Keunchil
    Gottfried, Maya
    Britschgi, Christian
    Le, Xiuning
    Paik, Paul
    ANNALS OF ONCOLOGY, 2021, 32 : S290 - S290
  • [33] PREVALENCE OF MET EXON 14 (METEX14) SKIPPING IN PATIENTS WITH ADVANCED NSCLC: A SYSTEMATIC LITERATURE REVIEW
    Pfeiffer, B.
    Garcia, A.
    Gezin, A.
    Heeg, B.
    Vioix, H.
    VALUE IN HEALTH, 2021, 24 : S40 - S40
  • [34] Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report
    Torrado, Carlos
    Feng, Jamie
    Faour, Elizabeth
    Leighl, Natasha B.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
  • [35] Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR EXon 20 Insertion Mutations: A Phase 1 Trial
    Duan, Jianchun
    Wu, Lin
    Yang, Kunyu
    Zhao, Jun
    Zhao, Yanqiu
    Dai, Xiumei
    Li, Mingjun
    Xie, Yanyan
    Yao, Yu
    Zhao, Mingfang
    Zhou, Chengzhi
    Ren, Xiubao
    Liu, Zhe
    Pan, Yueyin
    Li, Yuping
    Liu, Baogang
    Cheng, Ying
    Miao, Liyun
    Yu, Qitao
    Zhang, Zhihong
    Liu, Xiaoqing
    Cui, Jiuwei
    Zhang, Yu
    Zhang, Li
    Li, Xiaoyan
    Li, Xiaoling
    Shen, Bo
    Chen, Bi
    Zeng, Shan
    Li, Bin
    Hu, Yanping
    Li, Lin
    Wu, Rong
    Song, Qibin
    Wang, Jie
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (02) : 314 - 324
  • [36] Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
    Tanaka, Hisashi
    Taima, Kageaki
    Makiguchi, Tomonori
    Nakagawa, Junichi
    Niioka, Takenori
    Tasaka, Sadatomo
    CANCER COMMUNICATIONS, 2021, 41 (01) : 83 - 87
  • [37] Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States
    Cai, Beilei
    Zhou, Zheng-Yi
    Xue, Weiguang
    Hazra, Nisha C.
    Singh, Mukesh
    Mishra, Dinesh
    Brixner, Diana
    Oderda, Gary
    Biskupiak, Joseph
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 131 - 139
  • [38] Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14
    Kanemura, Hiroaki
    Takeda, Masayuki
    Shimizu, Shigeki
    Nakagawa, Kazuhiko
    THORACIC CANCER, 2021, 12 (04) : 549 - 552
  • [39] Efficacy and safety outcomes of ABN401 in NSCLC patients with MET Exon 14 Skipping: A clinically relevant subgroup analysis
    Lee, Se-Hoon
    Han, Ji-Youn
    Lee, Ki Hyeong
    Lee, Gyeong-Won
    Lemech, Charlotte
    Millward, Michael
    Roohullah, Aflah
    Le, Xiuning
    Park, Keunchil
    Choi, Jun Young
    Kim, Na Young
    Im, Sunyhe
    Rajasekaran, Nirmal
    Park, Kyung Eui
    Lee, Sangsuk
    Moon, Hanlim
    Hwang, Sunjin
    Shin, YoungKee
    Lee, Dae Ho
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [40] Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation
    Liu, Zhenkun
    Li, Pengfei
    Wu, Qiang
    Zhou, Qinghua
    ASIAN JOURNAL OF SURGERY, 2024, 47 (04) : 1851 - 1852
12345